Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 7,600 shares, adropof86.1% from the July 15th total of 54,500 shares. Based on an average daily volume of 99,800 shares, the short-interest ratio is presently 0.1 days. Approximately0.0% of the shares of the stock are sold short. Approximately0.0% of the shares of the stock are sold short. Based on an average daily volume of 99,800 shares, the short-interest ratio is presently 0.1 days.
Novozymes A/S Price Performance
Shares of NVZMY traded down $0.24 during midday trading on Monday, hitting $64.75. The company's stock had a trading volume of 434 shares, compared to its average volume of 36,852. The company's fifty day simple moving average is $70.13 and its two-hundred day simple moving average is $64.78. The stock has a market capitalization of $30.32 billion, a price-to-earnings ratio of 40.98, a price-to-earnings-growth ratio of 1.23 and a beta of 0.90. Novozymes A/S has a one year low of $53.95 and a one year high of $75.99. The company has a quick ratio of 1.04, a current ratio of 1.66 and a debt-to-equity ratio of 0.11.
Novozymes A/S Company Profile
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Recommended Stories
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.